S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands

Eliem Therapeutics (ELYM) Stock Price, News & Analysis

$2.73
-0.02 (-0.73%)
(As of 02/29/2024 ET)
Today's Range
$2.66
$2.73
50-Day Range
$2.56
$2.97
52-Week Range
$2.34
$4.25
Volume
9,341 shs
Average Volume
5,062 shs
Market Capitalization
$75.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Eliem Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
119.8% Upside
$6.00 Price Target
Short Interest
Healthy
0.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.16 out of 5 stars

Medical Sector

623rd out of 957 stocks

Pharmaceutical Preparations Industry

289th out of 433 stocks


ELYM stock logo

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

ELYM Stock Price History

ELYM Stock News Headlines

Checkpoint Therapeutics Inc CKPT
Eliem Therapeutics Inc ELYM
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Eliem Therapeutics GAAP EPS of -$0.84
SVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)
ELYM Eliem Therapeutics, Inc.
Eliem Therapeutics slashing staff amid leadership shakeup
See More Headlines
Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/29/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELYM
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+119.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-45,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.84 per share

Miscellaneous

Free Float
26,277,000
Market Cap
$75.27 million
Optionable
Not Optionable
Beta
0.44
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Andrew Levin M.D. (Age 46)
    Ph.D., Principal Financial Officer & Executive Chairman
    Comp: $73k
  • Dr. Valerie Morisset Ph.D. (Age 54)
    Chief Scientific Officer and Executive VP of Research & Development
    Comp: $617.87k
  • Ms. Emily Pimblett (Age 40)
    Principal Accounting Officer
  • Ms. Jo Palmer-Phillips Ph.D.
    Chief Development Officer














ELYM Stock Analysis - Frequently Asked Questions

Should I buy or sell Eliem Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ELYM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELYM, but not buy additional shares or sell existing shares.
View ELYM analyst ratings
or view top-rated stocks.

What is Eliem Therapeutics' stock price target for 2024?

1 analysts have issued 12-month price objectives for Eliem Therapeutics' shares. Their ELYM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 119.8% from the stock's current price.
View analysts price targets for ELYM
or view top-rated stocks among Wall Street analysts.

How have ELYM shares performed in 2024?

Eliem Therapeutics' stock was trading at $2.70 at the start of the year. Since then, ELYM shares have increased by 1.1% and is now trading at $2.73.
View the best growth stocks for 2024 here
.

When is Eliem Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ELYM earnings forecast
.

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.19.

When did Eliem Therapeutics IPO?

(ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Who are Eliem Therapeutics' major shareholders?

Eliem Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (7.91%), Northern Trust Corp (0.18%) and Cerity Partners LLC (0.05%).

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELYM) was last updated on 3/1/2024 by MarketBeat.com Staff